Top Markets
#1 Helium Helium +47.69%
#2 Pons Pons +37.87%
#3 TENDIES TENDIES +29.66%
#4 pipedog pipedog +22.25%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.17%
#7 Bounce Bounce +17.41%
#8 Songbird Songbird +12.58%
#9 Glidr Glidr +11.83%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +10.69%
Coin of the day
Helium Helium
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Shanghai Haohai Biological Technology Co., Ltd. Shanghai Haohai Biological Technology Co., Ltd.

Shanghai Haohai Biological Technology Co., Ltd.

688366
Peringkat dalam Saham #10462
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise... Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and distribution of advanced biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various international markets. The company's extensive product portfolio serves multiple medical fields. For ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, specialized orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. In orthopedics, they provide sodium hyaluronate injections and medical chitosan. Their wound care segment features recombinant human epidermal growth factor, effective in treating a broad spectrum of injuries, including burns, residual wounds, donor site trauma, post-traumatic wounds, and both acute and chronic ulcerations. Anti-adhesion solutions are offered in the form of medical sodium hyaluronate gel and medical chitosan, while hemostatic products include collagen sponges and porcine fibrin sealants. Within medical aesthetics, Shanghai Haohai produces a diverse range of hyaluronic acid (HA) dermal fillers: Matrifill, a first-generation mono-phase injectable gel; Janlane, a second-generation filler engineered for dynamic applications; and Hyalumatrix, a third-generation product designed for precise aesthetic enhancements. This division also supplies radio frequency devices and laser equipment. Beyond its core product offerings, the company actively pursues research and development in biological engineering and pharmaceutical innovations. It also provides related technology transfer and consultation services, alongside engaging in investment and trading activities. Originally established in 2007 as Haohai Limited, the company adopted its current name, Shanghai Haohai Biological Technology Co., Ltd., in 2010 and is headquartered in Shanghai, China.
Harga Saham
$4.39
Terakhir disinkronkan: 2026-08-28
Kapitalisasi Pasar
$835.72M
Perubahan (1 hari)
0.33%
Perubahan (1 tahun)
-42.81%
Negara
CN
Perdagangan Shanghai Haohai Biological Technology Co., Ltd. (688366)

Kategori

Healthcare
Rasio P/E untuk Shanghai Haohai Biological Technology Co., Ltd. (688366)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Shanghai Haohai Biological Technology Co., Ltd., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Shanghai Haohai Biological Technology Co., Ltd. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.